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CLINICAL INVESTIGATION
Glucose-induced insulin secretion in uremia: Effects of
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Glucose-induced insulin secretion in uremia: Effects of aminophylline
infusion and glucose loads. To explain mechanisms responsible for
derangement of insulin release in uremia, we investigated glucose
metabolism through three different tests in 14 patients with end-stage
chronic renal failure. These tests were: intravenous glucose tolerance
test with 0.33 g/kg of glucose solution (IVGTF); IVGTT with 0.5 glkg of
glucose solution (IVGTT2); IVGTT during aminophylline infusion
(IVGTT+A). Twelve of the patients had IVGTF repeated after two to
four months of thrice-weekly regular hemodialysis (IVGTT3). In each
test we measured plasma glucose (G), immunoreactive insulin (IRI) and
C-peptide. We also calculated glucose constant decay (K), insulin
production (IRI area), insulinogenic index (101), and insulin resistance
index (RI). Twenty-nine healthy volunteers formed the normal controls
for IVGTT. As compared to controls, during IVGTF uremic patients
showed significantly lower values in K, IRI area and 101, and showed
a significant RI value increase. During IVGTf2, IRI area values were
higher than during IVGTT but IGI and K values were unchanged.
During IVGTT+A both IRI area and 101 values were higher than during
LVGTT. After hemodialysis treatment (IVGTT3) K, IRI areas and 101
increased significantly as compared to the predialysis period. K in-
crease after hemodialysis correlated directly to lGI increase and
inversely to RI changes. 101 increase during IVGTT3 was directly
correlated to IGI rise during IVGTT+A. From these data we infer that
defective insulin release in uremia is due to a decrease of /3-cell glucose
sensitivity rather than to their functional exhaustion. An impaired
adenyl cyclase-cAMP system may have an important role in the
pathogenesis of this abnormality.
The presence of impaired glucose metabolism in uremic
patients has long been recognized [1—3]. Tissue insensitivity to
insulin is the primary cause [4, 5], but several reports suggest
that abnormalities in insulin secretion may have, in some
patients, an important role in its pathogenesis [6—10]. Indeed,
after oral or intravenous glucose administration [7, 8] or during
hyperglycemic clamp technique [10], some authors noticed that
early insulin response is lower in uremic patients than in
controls if compared to the magnitude of pancreatic 13-cell
glicidic stimulation or to insulin resistance degree. Moreover,
recent studies in vitro [11] confirmed that the initial phase of
glucose-induced insulin release is decreased in uremic rats.
However, the underlying pathogenetic mechanism contributing
to this derangement in insulin secretion is still unclear. Some
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authors [12] believe that a progressive functional exhaustion of
pancreatic /3-cells has a key role. On the other hand, other
authors [9] believe that uremia decreases p-cell sensitivity to
glucose stimulation.
To explain mechanisms responsible for this derangement in
insulin secretion we investigated in uremic patients the pancre-
atic /3-cell secretory ability following two stimulations of dif-
ferent intensities (0.33 g/kg and 0.5 glkg intravenous glucose
load). Furthermore, in the same patients, we studied changes in
glucose-induced insulin release to aminophylline infusion. Ami-
nophylline indeed, through competitive inhibition of phospho-
diesterase, raises intracellular cyclic AMP (cAMP) that plays an
important role in the modulation of glucose-induced insulin
release [13—20].
Methods
Fourteen undialyzed patients (8 males and 6 females) be-
tween 23 and 75 years of age (49.6 4.2; mean SE), with
end-stage chronic renal failure (ESRF; serum creatinine higher
than 9 mg/dl), were studied. All of them had negative histories
of hepatic and endocrine disorders, negative family histories of
diabetes mellitus and no known glucose intolerance before the
onset of renal failure. Their primary diseases were: chronic
glomerulonephritis in five cases, chronic pyelonephritis in four
cases (superimposed to interstitial nephritis in one and to
obstructive uropathy in two cases), nephrosclerosis in three
cases, and polycystic kidneys in two cases. None of them had
hyperkalemia or severe metabolic acidosis. All patients were
instructed to have a diet containing at least 250 g/day of
carbohydrates during three days before each examination.
Their body weight varied between 90 and 110% of ideal body
weight [21].
In all patients three tests were performed with 24 to 48 hour
intervals between each examination:
1) Intravenous glucose tolerance test (IVGTT). After over-
night fasting 0.33 g/kg of glucose solution was intravenously
injected in two minutes. Blood sampling was made before and
2, 5, 15, 30, 45, 60 minutes after injection using 0.5 mg/mI of
EDTA monoiodoacetate as antiglycolytic anticoagulant.
2) IVGTT using 0.5 glkg of glucose solution (IVGTT2).
3) IVGTT during aminophylline intravenous infusion (240 mg
rapidly 30 minutes before glucose administration followed by 2
mg/ml/min slow infusion) (JVGTT+A). In this test one more
blood sample was taken before aminophylline injection.
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Table I. Glucose metabolism parameters value in patients with ESRF after different dynamic tests
K
IRI area tU/ml IG1
0— 15 mm 15—60 mm 0—15 mm 15—60 mm RI
Controls
IVG'fl' 1.75 0.08 747 74 811 90 0.449 0.058 0.477 0.068 0.85 0.09
Uremics
IVGTT 0.84 0.08" 375 58 725 128 0.217 0041b 0.202 0.036" 1.41 025b
IVGTT2 0.91 0.10 527 83C 1349 2871 0.210 0.031 0.268 0.049 —
IVGTT+A 0.95 0.12 532 73 1247 247d 0.305 0.040" 0.414 0.068"
1VGT3 1.20 0.16" 697 155C 1119 369C 0.390 0.083" 0.413 0.112" 1.62 0.46"
P < 0.05, b p < 0.01 vs. Controls (Student's i-test for unpaired data)
P < 0.05, d P < 0.01 vs. IVGTT uremics (paired Student's 1-test)
In 12 patients the IVG1T was repeated after two to four
months of thrice-weekly regular hemodialysis (IVGTT3) in the
morning following the second weekly treatment. Dialysis
schedule was as follows: four hours x three per week, hollow
fiber or plate dialyzer with 0.9 to 1.06 square meter surface and
8- thickness cuprophan membrane, blood flow 250 to 300
mI/mm, and dialisate flow 500 mI/mm.
During the follow-up all patients took no drugs such as
calcium, vitamin D derivates, /3-blocking agents or diuretics.
Twenty-nine healthy volunteers between 23 and 65 years of
age (42.7 2.1) formed the normal controls for IVGTT.
Plasma glucose (0) was measured according to glucose
oxidase method, immunoreactive insulin (IRI) and C-peptide by
radioimmunoassay (Biodata). For each test glucose constant
decay (K) was calculated. G, IRI and C-peptide were also
expressed as area of response in early (0 to IS mm) and late (IS
to 60 mm) phase of stimulation (area of response above the
basal area as calculated by trapezoidal integration). Insulin
production was also evaluated considering entity of /3-cell
glucose stimulation by calculation of insulinogenic index (IGI)
(IRI arealG area ratio). Insulin resistance index (RI) was
calculated by IRI arealK ratio.
All data are presented as mean SE. Paired (in the same
patients) and unpaired (versus controls) Student's t-tests were
used for statistical analysis. Significance of linear correlations
was evaluated by Pearson's r and ANOVA table.
Results
Results are summarized in Table I. Compared to controls,
during IVGTT uremic patients showed significantly lower K
and 0 to IS minute IRI area values. No differences were found
between 15 and 60 minute IRI area values in the two groups.
However, IGI values in uremic patients were significantly lower
both in early and late phase of stimulation.
During IVGTI'2 in uremic patients both 0 to IS minute and 15
to 60 minute IRI area values were higher than during IVGTT,
but IGI and K values were unchanged. As shown in Table 2
only one patient (case no.8) exhibited a very low increase
(+ 7%) of insulin production after glucose load increase.
During IVGTT+A early and late insulin productions were
significantly higher than during IVGTT, both absolutely (IRI
areas) and relatively to the magnitude of pancreatic /3-cell
glucose stimulation (101). Even K values were higher than in
IVG1T but the difference did not reach statistical significance.
Aminophylline infusion alone did not affect 0 and IRI basal
Table 2. Insulin production in ESRF patients after two different
intravenous glucose loads (IVG1'T = 0.33 g/kg, IVG11'2 = 0.5 g/kg)
No.
case
IRI area, j.dJ/ml
%IVGTf IVGTF2
I 214 1392 +550
2 1620 2472 + 53
3 605 1047 +73
4 1173 1783 + 52
5 1024 1503 + 47
6 2377 3234 + 36
7 431 765 +77
8 936 1005 + 7
9 602 755 +25
10 1978 2537 + 28II 748 1176 + 57
12 1188 2130 + 79
13 1943 5765 +197
14 558 702 + 26
values. Both absolute and relative changes in insulin production
during the three tests in uremic patients are shown in Figure 1.
After hemodialysis treatment (IVGTT3) K, IRI areas and IGI
rose significantly as compared to IVGTT before hemodialysis,
while RI values were unchanged. However RI changes after
hemodialysis varied greatly among the various patients. Case
no.8 showed a reduction of both K and 101 values. Compared
to controls, K and IGI values during IVGTT3 did not show
significant differences, but IRI area values were higher.
In all patients the changes of C-peptide plasma values during
the various tests were parallel to changes of IRI plasma values.
This indicates that the differences in plasma IRI levels among
the various tests were due to different insulin release rates, and
not to changes in insulin kinetics.
K increase after hemodialysis (K3) is significantly correlated
directly to IGI increases (MGl3) and inversely to RI changes
(RI-j. The analysis of multiple linear regression equation is
reported in Table 3. Also, a significant positive relationship was
found between IGI3 and 101 increase during IVGTT+A
(zIGIA) (Fig. 2).
Discussion
Our results confirm that ESRF patients show impaired glu-
cose tolerance, insulin resistance, and reduced early insulin
release after glucose load [1—10]. However, in our data defec-
tive insulin production was present even in the late phase of
glycidic stimulation. Indeed, 15 to 60 minute insulin production
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Analysis:
Parameter Coefficient SE t P
iMGI3 0.27 0.08 3.27 0.008R1 —0.81 0.26 —3.07 0.012
= 0.01 + 0.27 MGI, — 0.81 Rl. No. cases = 12; r = 0.74; F =
5.41; P = 0.029.
during 1V01'T could be superimposed on control values if
evaluated absolutely as IRI area, but it was lower if evaluated
relative to magnitude of pancreatic 13-cell stimulation, as IGI.
The causes of this reduced insulin production are unclear. De
Fronzo and Alvestrand [9], after thrice-weekly hemodialysis,
found that changes in insulin response after glucose load in
uremic patients are inversely correlated to changes in tissue
sensitivity. Notably in patients with small changes in insulin
resistance, glucose metabolism improvement was due almost
entirely to insulin production increase. By these data the
authors believe that, in some uremic patients, uremia decreases
/3-cell sensitivity to glucose stimulation. Conversely, Carducci
Artenisio, Saitta and Bellinghieri [12] believe that insulin pro-
duction in uremia passes from a phase of compensatory hyper-
insulinemia (normal IGI and high insulin plasma values) to a
phase of hypoinsulinemia, at first relative (IGI decrease and
normal insulin plasma values) and later absolute (both 101 and
insulin plasma values decrease), due to progressive functional
exhaustion of pancreatic 13-cells.
Our data seem to exclude the hypothesis of functional ex-
haustion of pancreatic /3-cells in uremia due to attempt to
compensate insulin resistance. In such a situation 13-cells should
have reached their highest secretion capability and an incre-
ment of insulin response should not be possible at all, at least in
patients with impaired glucose tolerance. On the contrary, in
our investigation we found that glucose loading and phospho-
diesterase inhibition, by aminophylline, were able to increase
glucose-induced insulin response in ESRF patients. The rise in
insulin production during !VGTT+A did not cause a significant
improvement of K values in our patients. This may be due to
opposite effects of aminophylline on glucose metabolism. Ami-
nophylline not only stimulated release of insulin but also
catecholamines that in turn induced glycogenolysis.
The causes of defective insulin production in uremia may be
due to a previous phase of hormone release, more exactly to an
impaired reception and/or intracellular transmission of glucose
stimulus.
IRI area increases without IGI increases in uremic patients
during IVGTf2 compared to 1VGT1', may suggest the existence
of a reduced pancreatic /3-cell glucose sensitivity, according to
De Fronzo et al [9]. In fact these data show that glucose-
induced insulin release in uremia is correlated to magnitude of
glucose stimulation but it is lower than in controls.
Furthermore, after hemodialysis treatment 101 goes back to
normal values and K improvements are correlated to 101
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FIg. 1. Comparison among 0 to 60 minute fRi areas and IGI values
during three dynamic tests in non-dialyzed uremic patients. Symbols
are: (0) IVGTF; (1) IVGT1'2; (0) IVGTT+A.
Table 3. Relationship between changes in K (AK,) and changes in
IGI (MGI3) and RI (R1) after starting of maintenance hemodialysis
in ESRF patients
1 2 3 4 5
FIg. 2. Relationship between IGI increase after starting of mainte-
nance hemodialysis (MGI3) and IGI increase during aminophylline
infusion (MG1A) in ESRF patients. y = —1.2 + I .9x. r = 0.78. P < 0.01.
L NS
P< 0.01
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increases as well to RI decreases. These data indicate that
removal of low molecular weight uremic toxins by hemodialysis
is able to restore 13-cell secretory ability. There is the possibility
that chronic hemodialysis therapy for a period of some months
might have improved overall metabolism and increased muscle
mass that would in turn provide a net increase in the number of
glucose receptor sites and reduce insulin resistance. However,
all of our patients but one showed after hemodialysis a K values
improvement despite the highly variable RI changes. Also other
investigators [I] have shown an immediate effect of dialysis on
glucose utilization rates and insulin secretion which has been
assumed to result from removal of uremic toxins.
The hypothesis of decreased 13-cell glucose sensitivity in
uremia is also supported by report of Nakamura et al [Ii]. The
authors found that the initial insulin release from column-
perifused isolated islets in the presence of glucose is signifi-
cantly lower in uremic than in control rats without differences in
insulin content of islets.
"Uremic toxins" may reduce 13-cell glucose sensitivity by
acting on intracellular glucose utilization, which is the main
mechanism responsible for insulin release and biosynthesis [13,
14, 16, 22—25]. Indeed, some authors [26—28] found a reduction
of several enzyme activities of glycolytic pathways in extrapan-
creatic tissues of uremic patients.
Alternatively uremic toxins may affect the adenyl cyclase-
cAMP system, which is the main intracellular modulator of
glucose-induced insulin release [13—20]. In our study, we found
that the increase in intracellular cAMP by phosphodiesterase
inhibition through aminophylline infusion is able to restore the
glucose sensitivity of pancreatic 13-cells. We also found a
significant positive relationship between IGI3 and MGIA. This
may indicate that an impaired adenylcyclase-cAMP system
plays an important role in the pathogenesis of defective insulin
release in ESRF.
The hypothesis of some authors [11] that vitamin D defi-
ciency has the most important role in the pathogenesis of insulin
release derangement in uremia seems unacceptable. In our
patients improvement of 13-cell glucose response after hemodi-
alysis occurred without calcium and/or vitamin D derived
supplementation.
From this investigation we may infer that defective insulin
release in ESRF is due to a decrease of 13-cell glucose sensitivity
more than to their functional exhaustion.
Functional exhaustion of 13-cells may play an adjunctive role
in a few patients with very high RI values and/or long-term
insulin resistance andlor genetic predisposition. In our study
only one patient was incapable of increasing insulin production
after an increased glucose load. This patient even showed a
reduction of IGI and K after starting maintenance hemodialysis.
In a previous investigation [29], we also found that insulin
resistance-induced 13-cell functional exhaustion is very small in
long-term hemodialysis patients.
Reprint requests to Dr. Vincenzo Allegra, Servizio Emodia!isi,
Ospedale Civile, 33057 Palmanova, Italy.
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